AstraZeneca's regulatory filings for IMFINZI plus enfortumab vedotin are currently being reviewed in the EU, Japan, and other countries, following the FDA Priority Review.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
